About
Parasma is building biological-compute systems that train human brain cells for AI workloads, using algorithms that turn neural activity into computation. Its showcased applications include token prediction and reinforcement learning; unlike conventional GPU-only approaches, it directly decodes neuronal responses and aims to reduce AI’s energy strain for AI-compute users.
Market
Parasma competes in the emerging biological-computing and AI-infrastructure market, using living neural tissue as an alternative computational substrate with the stated goal of reducing AI's energy burden. Its public positioning is algorithm- and training-focused: it writes algorithms to turn brain cells into compute and demonstrates token prediction and reinforcement learning, whereas Cortical Labs emphasizes deployable neuron-on-chip hardware and cloud access, FinalSpark emphasizes a remote organoid research platform, and The Biological Computing Co. emphasizes neuron-derived software optimization for existing AI models.
Parasma's best-supported target customers are AI research organizations, machine-learning developers, and neurotechnology/biocomputing research groups interested in lower-energy alternatives to conventional AI compute. The company appears aimed initially at technically sophisticated early adopters rather than a broad established enterprise segment; no named customers or formal buyer segmentation are publicly identified in the available evidence.
At a Glance
Problem
Parasma is targeting the energy and economics of conventional AI compute. As AI workloads scale, dependence on GPUs and other accelerators brings substantial recurring power and infrastructure costs; Parasma’s stated ambition is to reduce AI’s energy strain by using living neural systems as a computational substrate. Its clearest current use case is biologically implemented AI rather than a finished enterprise application: token prediction and reinforcement learning, including the demonstration of human brain cells playing Doom.
Product / Service
Parasma describes its product as the algorithms and interfaces that turn brain cells into programmable compute. For token prediction, a sentence is converted into an electrical stimulation pattern, the neurons carry the context, and their responses are decoded directly into tokens, with the company explicitly presenting this pathway as requiring no GPU. For reinforcement learning, each frame becomes a stimulation pattern; the neurons choose an action, the result is measured, and feedback is delivered in a changing environment.
The public materials point to a software-and-algorithm layer operating biological hardware, rather than a broadly deployed hardware product or cloud service. The potential benefit is compute that exploits the adaptive behavior of living neurons and could reduce the energy burden of some AI workloads, although the available evidence does not establish a production benchmark or quantified cost advantage.
Market
Parasma operates at the intersection of biological computing, machine learning, neurotechnology, and AI infrastructure. Its most direct biological-computing comparables are Cortical Labs, which sells the CL1 biological computer and offers a biological cloud, and FinalSpark, which provides remote access to living-neuron experiments through its Neuroplatform. It also competes indirectly with conventional AI-compute providers and accelerator makers such as Nvidia, Intel, AMD, and Cerebras; Tracxn additionally lists Neuralink, Synchron, and CorTec as competitors, although those companies are more closely associated with neural interfaces or neurotechnology than with Parasma’s specific compute approach.
Parasma is very early-stage rather than a proven commercial business. It was founded by Sean Cole in 2026, is an active Y Combinator Summer 2026 company, lists a one-person team, and is hiring a founding scientist. Its visible traction is technical and reputational: the brain-cells-playing-Doom demonstration, open-source work that had 245 GitHub stars and 27 forks in the retrieved record, and YC backing. A third-party funding database reports $500,000 raised in a June 2026 seed round from Y Combinator, while the reviewed materials disclose no paying customers or revenue, so it is best characterized as pre-revenue or at the earliest commercialization stage.
Founders & Leadership
Funding History
Y Combinator
Recent News
The report lists Parasma as raising a $0.5 million pre-seed round to develop computational algorithms using human brain cells. It also identifies Y Combinator as a backer.
A Tracxn competitor-profile update reports that Parasma secured $500,000 in funding in June 2026, corroborating the pre-seed financing reported elsewhere.
Y Combinator’s company profile introduced Parasma as a Summer 2026 company founded by Sean Cole. The profile says Parasma writes algorithms that turn brain cells into compute and highlights its demonstration of human brain cells playing Doom.
Parasma announced that it had joined Y Combinator and thanked the accelerator’s partners for backing the company at an early stage. This is the company’s primary accelerator-backing announcement found during the period.
Parasma’s public site described its product as training human brain cells for compute, including token prediction and reinforcement-learning applications. Its broader positioning is software and infrastructure that turn living neurons into programmable compute.
Active Roles
1Business Model
Parasma appears to be pursuing a B2B platform model: it develops algorithms and biological-compute infrastructure, with the intended commercial offering likely involving access to or use of neuron-based AI compute. Public evidence does not disclose pricing or operating revenue; the company is instead described as an early YC-backed biological-compute platform.